SmartestCrowd
Organizations
Orgs
No organizations
Projects
No projects
0
0
Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC - Targeted Oncology
1/22/23 at 3:34am
Organization
Targetedonc.com
Authors
Tony Berberabe
MPH
48 words
0
Comments
The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.
Cancer
Business & Industrial
Bevacizumab
Tipiracil Boosts Survival
Trifluridine
mCRC
Oncology The SUNLIGHT
Josep Tabernero
You are the first to view
https://www.targetedonc.com/view/adding-bevacizumab-to-trifluridine-tipiracil-boosts-survival-disease-control-rate-in-mcrc
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...